Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Ally Financial
ALLY
5
Bank of America
BAC
AU Stock MarketDetailed Quotes
IMM Immutep Ltd
- 0.280
- -0.010-3.45%
20min DelayNot Open May 14 16:00 AET
407.57MMarket Cap-7.78P/E (Static)
0.295High0.280Low3.59MVolume0.290Open0.290Pre Close1.02MTurnover0.48552wk High0.29%Turnover Ratio1.46BShares0.22252wk Low--EPS TTM346.33MFloat Cap9.000Historical HighLossP/E (Static)1.24BShs Float0.050Historical Low-0.036EPS LYR5.17%Amplitude--Dividend TTM2.35P/B1Lot Size--Div YieldTTM
About Immutep Ltd Company
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
Company Profile
SymbolIMM
Company NameImmutep Ltd
Founded1987
MarketASX
Employees44
Fiscal Year Ends06-30
Address264 George Street Level 32, Australia Square
CitySydney
CountryAustralia
Zip Code2000
Phone+61 283157003
Websitehttps://www.immutep.com
Share RegistryBOARDROOM PTY LIMITED
LEVEL 8, 210 GEORGE STREET, SYDNEY, NSW, AUSTRALIA, 2000
(02) 9290 9600
Company Executives
- Name
- Position
- Salary
- Marc Voigt
- Director, Chief Executive Officer and Chief Financial Officer
- 1.06M
- Professor Dr. Frederic Triebel, M.D.
- Executive Director and Chief Scientific Officer
- 864.44K
- Deanne Miller
- Chief Operating Officer, General Counsel and Company Secretary
- 565.23K
- Dr. Florian Vogl, M.D.,PhD
- Chief Medical Officer
- 955.82K
- Pete A. Meyers
- Deputy Chairman of the Board
- 138.71K
- Dr. Russell J. Howard, PhD
- Chairman of the Board
- 222.02K
- Lis Boyce
- Independent Director
- 144.76K
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting